BIOMARK TO OPEN A DIAGNOSTIC LABORATORY IN QUÉBEC

BioMark Lab in Quebec

Vancouver, British Columbia – (April 29, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy platform for early lung cancer detection, monitoring and predicting response to treatment.

The company’s aim is to obtain regulatory approval and clinical laboratory licenses to be fully operational in early 2022 and start offering its metabolomics biomarker panel for early lung cancer detection to physicians initially across the Province of Quebec. BioMark’s technology alliance with Quebec-based Phytronix Technologies Inc. enhanced its technical capabilities with extensive automated sample preparation and mass spectrometry assay development that prompted the opening of its own diagnostic laboratory.

“This move to Quebec City represents the successful accomplishment of our strategic plan to bring the company to its pre-commercialization stage. The fact that BioMark is spearheading the commercialization of its assay from its own clinical laboratory in Quebec, Canada and later across North America will certainly create more value for our shareholders.” said Rashid Bux, CEO of BioMark.

Dr Jeff Haince Chief Science Officer

In conjunction with expanding our infrastructure in Quebec, BioMark is also pleased to report that Dr. Jean-François (Jeff) Haince will be leading our laboratory operation as General Manager for BDS. Rashid Ahmed, President and CEO, says, “We are delighted that Jeff decided to join our management team and lead our operation as he has been instrumental in setting up our lab infrastructure and capacity.

Jeff possesses an excellent understanding of the whole value chain and regulatory landscape in the molecular diagnostic field and has played a vital role in the commercialization of two early cancer detection molecular diagnostics. Jeff’s experience is poised to propel our transition from being research and development focused to a commercialization driven entity”.

About Phytronix Technologies Inc.

Phytronix Technologies Inc. is a privately-owned company based in Québec City, Canada, and was founded in 2000. Phytronix invented and patented the Laser Diode Thermal Desorption (LDTD) technology for mass spectrometry. The company introduced the Luxon Ion Source®, which is the second-generation apparatus based on the patented-LDTD® technology and currently the fastest technology for mass spectrometry. This innovative technology enables ultra-high-speed analysis in less than 4 seconds per sample. The company will provide the optimized internal standards that are necessary for use in clinical settings, along with technical expertise required with high-throughput mass spectrometry.

Press Release – BIOMARK TO OPEN A DIAGNOSTIC LABORATORY IN QUÉBEC

Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.